Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Feb;210(1):205-213.
doi: 10.1007/s10549-024-07553-x. Epub 2024 Dec 4.

The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study

A Di Leone  1 , A Filippone  2 , C Maggiore  2 , M M Rossi  2 , C Rossi  2 , A Di Micco  2 , Luana Forcina  2 , A Franco  3 , L Ionta  1 , A Fabi  4 , I Paris  5 , L Scardina  1 , A M Sanchez  1 , P C Pafundi  6 , G Franceschini  1 , R Masetti  1 , S Magno  1   2
Affiliations
Observational Study

The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study

A Di Leone et al. Breast Cancer Res Treat. 2025 Feb.

Abstract

Purpose: Neoadjuvant chemotherapy (NAC) has a well-established role in locally advanced or chemoresponsive breast cancers (BC). Chemotherapic regimens are effective when patients receive the optimal doses. Toxicities are common in overweight/obese patients but may occur also in normal weight counterparts. This leads to delays, reductions, or discontinuation of treatment, with impact on outcomes. Current dosing is based on body weight and predicted Body Surface Area (BSA). These parameters do not take into consideration the individual variations of fat mass (FM) and fat-free mass (FFM) that affect pharmacokinetics. Assessment of body composition (BoCo), rather than Body Mass Index (BMI), could help to better plan chemotherapy and reduce drug-related toxicities. Our aim was to analyze the correlations between body weight, anthropometric measures, BoCO, and toxicities related to NAC in non-metastatic BC patients.

Methods: This is a retrospective observational cohort study that includes 120 consecutive BC patients undergoing NAC, enrolled between May 2018 and December 2020. All patients received an evaluation of anthropometric parameters (height, weight, waist and hip circumference, BMI) and an assessment of BoCo using Segmental Multi-Frequency-Bioelectrical Impedance Analysis.

Results: A logistic regression models confirmed that a higher FM was associated with a higher rate of neurological and hematologic toxicities in protocols containing Platinum. Moreover, patients with a low FFM% have a higher risk for hematologic toxicity in protocols containing Platinum.

Conclusion: A routine assessment of BoCo, in addition to evaluation of anthropometric measures and BMI, could allow to personalize chemotherapy doses, in order to reduce chemotherapy-related toxicities.

Keywords: Body composition; Breast cancer; Neoadjuvant chemotherapy; Personalized medicine; Toxicity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Polyclinic University A. Gemelli, IRCCS with the number 5357 and it was retrospectively registered.

Similar articles

See all similar articles

Cited by

References

    1. Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485–1505. 10.1200/JCO.20.03399 - PMC - PubMed
    1. Burstein HJ, Lacchetti C, Anderson H et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438. 10.1200/JCO.18.01160 - PubMed
    1. Muss HB, Berry DA, Cirrincione C et al (2007) Cancer and leukemia group B experience. toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J Clin Oncol 25(24):3699–704. 10.1200/JCO.2007.10.9710 - PubMed
    1. Schwenkglenks M, Pettengell R, Jackisch C et al (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU prospective observational European neutropenia study. Support Care Cancer 19(4):483–490. 10.1007/s00520-010-0840-y - PubMed
    1. Di Leone A, Terribile D, Magno S et al (2021) Neoadjuvant chemotherapy in breast cancer: An advanced personalized multidisciplinary prehabilitation model (APMP-M) to optimize outcomes. J Pers Med 11(5):324. 10.3390/jpm11050324 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources